NEW YORK (TheStreet) -- Medtronic (MDT - Get Report) shares are climbing on Thursday, up 1.9% to $65.01, after the medical equipment company announced the preliminary outcomes for its Micra TPS cardiac pacemaker tests.
The company announced that after one and three month intervals, test results showed that the world's smallest pacemaker was successfully implanted in all patients involved in the test with ages ranging from 74 to 83 years.
The device -- which has not yet been approved in the U.S. -- does not require a surgical incision and is one-tenth the size of conventional pacemakers.
Must Read: Warren Buffett's 25 Favorite Stocks
Medtronic has had a busy week following reports on Tuesday that it was raising a $16.3 billion senior unsecured bridge loan to help finance its proposed $43 billion acquisition of Covidien Plc (COV).
TheStreet Ratings team rates MEDTRONIC INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:
"We rate MEDTRONIC INC (MDT) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income."
Highlights from the analysis by TheStreet Ratings Team goes as follows:
- Despite its growing revenue, the company underperformed as compared with the industry average of 3.6%. Since the same quarter one year prior, revenues slightly increased by 2.4%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- Net operating cash flow has increased to $1,328.00 million or 11.87% when compared to the same quarter last year. In addition, MEDTRONIC INC has also modestly surpassed the industry average cash flow growth rate of 7.50%.
- MDT's debt-to-equity ratio of 0.61 is somewhat low overall, but it is high when compared to the industry average, implying that the management of the debt levels should be evaluated further. Even though the debt-to-equity ratio shows mixed results, the company's quick ratio of 3.24 is very high and demonstrates very strong liquidity.
- Compared to where it was a year ago today, the stock is now trading at a higher level, regardless of the company's weak earnings results. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
- You can view the full analysis from the report here: MDT Ratings Report